•
Mar 28, 2020

Waters Q1 2020 Earnings Report

Waters' Q1 2020 financial performance was impacted by COVID-19, leading to a sales decline and reduced earnings per share.

Key Takeaways

Waters Corporation reported a 10% decrease in sales to $465 million for Q1 2020, with GAAP EPS decreasing to $0.86 and non-GAAP EPS decreasing to $1.15. The company implemented cost reduction plans and revised capital deployment plans in response to COVID-19 uncertainties.

Sales declined by 10% to $465 million, or 8% in constant currency.

GAAP EPS was $0.86, while non-GAAP EPS was $1.15, a 28% decrease from the previous year.

A cost reduction plan of approximately $100 million for the year was implemented.

Full-year 2020 financial guidance was withdrawn due to COVID-19 uncertainties.

Total Revenue
$465M
Previous year: $514M
-9.5%
EPS
$1.15
Previous year: $1.6
-28.1%
Pharma Market Sales
272,563,000%
Previous year: 294,512,000%
-7.5%
Industrial Market Sales
143,354,000%
Previous year: 155,218,000%
-7.6%
Academic & Gov Sales
49,022,000%
Previous year: 64,132,000%
-23.6%
Gross Profit
$254M
Previous year: $293M
-13.2%
Cash and Equivalents
$394M
Previous year: $685M
-42.5%
Free Cash Flow
$121M
Total Assets
$2.67B
Previous year: $3.25B
-17.9%

Waters

Waters

Waters Revenue by Geographic Location

Forward Guidance

Waters withdrew its full-year 2020 financial guidance due to the evolving and significant uncertainties related to the impact of the COVID-19 pandemic.

Revenue & Expenses

Visualization of income flow from segment revenue to net income